Gilead Sciences, Inc. (GILD) is Krensavage Asset Management LLC’s 3rd Largest Position
Krensavage Asset Management LLC reduced its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 0.9% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 532,434 shares of the biopharmaceutical company’s stock after selling 4,587 shares during the quarter. Gilead Sciences comprises 11.4% of Krensavage Asset Management LLC’s holdings, making the stock its 3rd largest position. Krensavage Asset Management LLC’s holdings in Gilead Sciences were worth $37,686,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors also recently added to or reduced their stakes in the business. First Allied Advisory Services Inc. raised its holdings in Gilead Sciences by 13.0% in the 2nd quarter. First Allied Advisory Services Inc. now owns 102,994 shares of the biopharmaceutical company’s stock valued at $7,287,000 after acquiring an additional 11,824 shares during the period. Graham Capital Management L.P. bought a new position in Gilead Sciences in the 2nd quarter valued at about $1,175,000. PDT Partners LLC raised its holdings in Gilead Sciences by 93.4% in the 2nd quarter. PDT Partners LLC now owns 177,200 shares of the biopharmaceutical company’s stock valued at $12,542,000 after acquiring an additional 85,577 shares during the period. Arete Wealth Advisors LLC raised its holdings in Gilead Sciences by 13.1% in the 2nd quarter. Arete Wealth Advisors LLC now owns 9,416 shares of the biopharmaceutical company’s stock valued at $666,000 after acquiring an additional 1,093 shares during the period. Finally, Frontier Wealth Management LLC raised its holdings in Gilead Sciences by 10.7% in the 2nd quarter. Frontier Wealth Management LLC now owns 133,631 shares of the biopharmaceutical company’s stock valued at $9,458,000 after acquiring an additional 12,870 shares during the period. 76.23% of the stock is currently owned by hedge funds and other institutional investors.
In other Gilead Sciences news, EVP Gregg H. Alton sold 25,000 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $82.65, for a total value of $2,066,250.00. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Robin L. Washington sold 51,820 shares of the firm’s stock in a transaction that occurred on Thursday, September 7th. The shares were sold at an average price of $85.00, for a total transaction of $4,404,700.00. Following the completion of the sale, the chief financial officer now owns 43,352 shares in the company, valued at approximately $3,684,920. The disclosure for this sale can be found here. Insiders have sold a total of 546,819 shares of company stock worth $41,808,839 in the last quarter. 1.30% of the stock is currently owned by company insiders.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.13 by $0.14. The business had revenue of $6.51 billion for the quarter, compared to analyst estimates of $6.40 billion. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The firm’s revenue for the quarter was down 13.2% on a year-over-year basis. During the same quarter last year, the business posted $2.75 EPS. analysts forecast that Gilead Sciences, Inc. will post 8.53 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, December 28th. Investors of record on Friday, December 15th will be given a dividend of $0.52 per share. The ex-dividend date of this dividend is Thursday, December 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.84%. Gilead Sciences’s dividend payout ratio is 23.69%.
GILD has been the topic of several research analyst reports. BidaskClub lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Wednesday, August 9th. Berenberg Bank restated a “buy” rating and set a $86.00 target price (up previously from $79.00) on shares of Gilead Sciences in a research report on Sunday, August 20th. Vetr lowered shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $82.15 target price on the stock. in a research report on Monday, August 28th. Maxim Group restated a “hold” rating on shares of Gilead Sciences in a research report on Monday, August 28th. Finally, Credit Suisse Group set a $79.00 target price on shares of Gilead Sciences and gave the stock a “buy” rating in a research report on Monday, August 28th. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $85.22.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.